HealthcareNSE · BSE

AstraZeneca Pharma India Ltd.

ASTRAZEN · ISIN INE203A01020

Share price

₹8,440▲ +0.20%

Market capitalisation

₹21100 Cr● Closed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹21100 Cr

Current price

₹8,440

+0.20% today

52W high

₹10,393

52W low

₹7,552

Stock P/E

112.58

P/B ratio

24.18

02 · Per share & returns

EPS (TTM)

₹74.97

Book value

₹349

ROE

22.83%

ROA

8.32%

Dividend yield

0.38%

Beta

0.25

03 · Financials (TTM)

By the numbers

Revenue

₹2276 Cr

+20.40% YoY

EBITDA

₹262 Cr

Net profit

₹188 Cr

-23.00% YoY

Profit margin

8.24%

Operating margin

9.56%

Total debt

₹111 Cr

Total cash

₹449 Cr

Debt / equity

0.13x

Current ratio

1.77x

Payout ratio

42.66%

04 · Analyst view

Target price

—

Upside

—

Consensus

NONE

Analysts

—

05 · Shareholding pattern

Who owns ASTRAZEN?

Promoters
75.00%
Founders & promoter group
Institutions
7.82%
FII + DII
Public
17.18%
Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol: ASTRAZEN
Exchange: NSE · BSE
CIN: —
ISIN: INE203A01020
BSE code: 506820
Sector: Healthcare
Industry: Healthcare
Face value: ₹2
Listing date: 03 May 2001
Employees: 600
Headquarters: Bengaluru, India
Website: www.astrazeneca.in

07 · About

What is AstraZeneca Pharma India Ltd.?

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

08 · Common questions

Frequently asked

What is the CIN of AstraZeneca Pharma India Ltd.?+

The Corporate Identity Number for AstraZeneca Pharma India Ltd. is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of AstraZeneca Pharma India Ltd.?+

Promoter holding in ASTRAZEN is approximately 75.00%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of AstraZeneca Pharma India Ltd.?+

AstraZeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of approximately ₹21100 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent